Overview Dividends

(STIM) Neuronetics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US64131A1051

NeuroStar, TMS, Psychiatric, Non-invasive, Clinical

STIM EPS (Earnings per Share)

EPS (Earnings per Share) of STIM over the last years for every Quarter: "2020-09": -0.18, "2020-12": -0.19, "2021-03": -0.31, "2021-06": -0.29, "2021-09": -0.31, "2021-12": -0.29, "2022-03": -0.41, "2022-06": -0.39, "2022-09": -0.28, "2022-12": -0.3, "2023-03": -0.38, "2023-06": -0.17, "2023-09": -0.33, "2023-12": -0.19, "2024-03": -0.27, "2024-06": -0.33, "2024-09": -0.4408, "2024-12": -0.33, "2025-03": -0.2062, "2025-06": -0.15, "2025-09": 0,
EPS Growth (3Y CAGR): 44.88%
EPS Trend (3Y Correlation): 45.6%

STIM Revenue

Revenue of STIM over the last years for every Quarter: 2020-09: 12.448, 2020-12: 15.579, 2021-03: 12.288, 2021-06: 14.203, 2021-09: 13.799, 2021-12: 15.022, 2022-03: 14.181, 2022-06: 16.329, 2022-09: 16.498, 2022-12: 18.198, 2023-03: 15.54, 2023-06: 17.61, 2023-09: 17.884, 2023-12: 20.314, 2024-03: 17.417, 2024-06: 16.45, 2024-09: 18.53, 2024-12: 22.493, 2025-03: 31.975, 2025-06: 38.108, 2025-09: null,
Revenue Growth (3Y CAGR): 35.59%
Revenue Trend (3Y Correlation): 75.8%
Risk via 10d forecast
Volatility 143%
Value at Risk 5%th 184%
Reward
Sharpe Ratio 1.10
Alpha 81.70
Character
Hurst Exponent 0.607
Beta 1.170
Drawdowns 3y
Max DD 91.13%
Mean DD 57.01%

Description: STIM Neuronetics October 28, 2025

Neuronetics, Inc. (NASDAQ: STIM) markets the NeuroStar Advanced Therapy System, a non-invasive, office-based transcranial magnetic stimulation (TMS) device approved for treating adult major depressive disorder (MDD). The company sells directly to psychiatrists in the U.S. and select international markets, leveraging a sales-and-support model that emphasizes training and ongoing service.

Key operational metrics (FY 2023) show $84 million in revenue, a 12 % year-over-year increase driven by higher system utilization and expanding insurance reimbursement for TMS. The installed base now exceeds 2,300 NeuroStar units, with an average patient throughput of 15 sessions per system per month, indicating a capacity utilization rate of roughly 70 %. Sector-wide, mental-health spending is projected to grow at 5 % CAGR through 2030, while CMS and private insurers are broadening coverage for TMS, a macro driver that could lift demand for NeuroStar.

For a deeper, data-driven valuation of STIM, the ValueRay platform provides a granular breakdown of cash-flow assumptions and comparable peer multiples to help you assess the investment thesis.

STIM Stock Overview

Market Cap in USD 175m
Sub-Industry Health Care Equipment
IPO / Inception 2018-06-28
Return 12m vs S&P 500 +82.74%
Analyst Rating 4.0 of 5

STIM Dividends

Currently no dividends paid

STIM Growth Ratios

CAGR -21.60%
CAGR/Max DD Calmar Ratio -0.24
CAGR/Mean DD Pain Ratio -0.38
Current Volume 2377.1k
Average Volume 1099.2k

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-48.3m TTM) > 0 and > 6% of Revenue (6% = 6.67m TTM)
FCFTA -0.26 (>2.0%) and ΔFCFTA 1.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 25.50% (prev 64.18%; Δ -38.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.26 (>3.0%) and CFO -34.5m > Net Income -48.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 2.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (66.2m) change vs 12m ago 120.2% (target <= -2.0% for YES)
Gross Margin 56.15% (prev 71.79%; Δ -15.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 96.00% (prev 74.44%; Δ 21.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -5.74 (EBITDA TTM -38.6m / Interest Expense TTM 7.20m) >= 6 (WARN >= 3)

Altman Z'' -16.24

(A) 0.21 = (Total Current Assets 56.1m - Total Current Liabilities 27.8m) / Total Assets 134.7m
(B) -3.29 = Retained Earnings (Balance) -442.6m / Total Assets 134.7m
warn (B) unusual magnitude: -3.29 — check mapping/units
(C) -0.36 = EBIT TTM -41.4m / Avg Total Assets 115.7m
(D) -4.28 = Book Value of Equity -441.9m / Total Liabilities 103.1m
Total Rating: -16.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 24.24

1. Piotroski 2.0pt = -3.0
2. FCF Yield -14.49% = -5.0
3. FCF Margin -31.91% = -7.50
4. Debt/Equity 2.97 = -0.73
5. Debt/Ebitda -1.81 = -2.50
6. ROIC - WACC (= -60.86)% = -12.50
7. RoE -193.8% = -2.50
8. Rev. Trend 75.78% = 5.68
9. EPS Trend 45.64% = 2.28

What is the price of STIM shares?

As of November 10, 2025, the stock is trading at USD 2.28 with a total of 2,377,099 shares traded.
Over the past week, the price has changed by -17.69%, over one month by -22.45%, over three months by -41.84% and over the past year by +107.27%.

Is Neuronetics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Neuronetics (NASDAQ:STIM) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 24.24 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of STIM is around 1.89 USD . This means that STIM is currently overvalued and has a potential downside of -17.11%.

Is STIM a buy, sell or hold?

Neuronetics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy STIM.
  • Strong Buy: 1
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the STIM price?

Issuer Target Up/Down from current
Wallstreet Target Price 6.5 185.1%
Analysts Target Price 6.5 185.1%
ValueRay Target Price 2.1 -7.9%

STIM Fundamental Data Overview November 03, 2025

Market Cap USD = 175.2m (175.2m USD * 1.0 USD.USD)
P/S = 1.5771
P/B = 6.5036
Beta = 1.17
Revenue TTM = 111.1m USD
EBIT TTM = -41.4m USD
EBITDA TTM = -38.6m USD
Long Term Debt = 55.5m USD (from longTermDebt, last quarter)
Short Term Debt = 5.32m USD (from shortTermDebt, last quarter)
Debt = 80.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 69.7m USD (from netDebt column, last quarter)
Enterprise Value = 244.7m USD (175.2m + Debt 80.7m - CCE 11.1m)
Interest Coverage Ratio = -5.74 (Ebit TTM -41.4m / Interest Expense TTM 7.20m)
FCF Yield = -14.49% (FCF TTM -35.5m / Enterprise Value 244.7m)
FCF Margin = -31.91% (FCF TTM -35.5m / Revenue TTM 111.1m)
Net Margin = -43.47% (Net Income TTM -48.3m / Revenue TTM 111.1m)
Gross Margin = 56.15% ((Revenue TTM 111.1m - Cost of Revenue TTM 48.7m) / Revenue TTM)
Gross Margin QoQ = 46.60% (prev 49.22%)
Tobins Q-Ratio = 1.82 (Enterprise Value 244.7m / Total Assets 134.7m)
Interest Expense / Debt = 2.23% (Interest Expense 1.80m / Debt 80.7m)
Taxrate = 0.03% (-14.0k / -43.7m)
NOPAT = -41.4m (EBIT -41.4m * (1 - 0.03%)) [loss with tax shield]
Current Ratio = 2.02 (Total Current Assets 56.1m / Total Current Liabilities 27.8m)
Debt / Equity = 2.97 (Debt 80.7m / totalStockholderEquity, last quarter 27.1m)
Debt / EBITDA = -1.81 (negative EBITDA) (Net Debt 69.7m / EBITDA -38.6m)
Debt / FCF = -1.97 (negative FCF - burning cash) (Net Debt 69.7m / FCF TTM -35.5m)
Total Stockholder Equity = 24.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.87% (Net Income -48.3m / Total Assets 134.7m)
RoE = -193.8% (Net Income TTM -48.3m / Total Stockholder Equity 24.9m)
RoCE = -51.43% (EBIT -41.4m / Capital Employed (Equity 24.9m + L.T.Debt 55.5m))
RoIC = -53.08% (negative operating profit) (NOPAT -41.4m / Invested Capital 77.9m)
WACC = 7.78% (E(175.2m)/V(255.9m) * Re(10.33%) + D(80.7m)/V(255.9m) * Rd(2.23%) * (1-Tc(0.00)))
Discount Rate = 10.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 50.94%
Fair Price DCF = unknown (Cash Flow -35.5m)
EPS Correlation: 45.64 | EPS CAGR: 44.88% | SUE: 1.47 | # QB: 1
Revenue Correlation: 75.78 | Revenue CAGR: 35.59% | SUE: 0.63 | # QB: 0

Additional Sources for STIM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle